Table 1 Clinical characteristics according to age group

Age, years

71 (67, 76)

54 (47, 59)

0.001

Male, n (%)

102 (70.8)

142 (83.0)

0.010

Body mass index, kg/m²

23.7 (20.8, 26.2)

24.5 (22.5, 27.1)

0.034

Current smoker, n (%)

49 (34.0)

86 (50.3)

0.004

Hypertension, n (%)

61 (42.4)

66 (38.6)

0.497

Diabetes mellitus, n (%)

44 (30.6)

44 (25.7)

0.342

Atrial fibrillation, n (%)

13 (9.0)

9 (5.3)

0.192

Prior SSE, n (%)

50 (35.0)

31 (18.1)

0.001

Antiplatelet therapy

112 (77.8)

128 (74.9)

0.544

Creatinine clearance, mL/min/1.73 m²

68.3 (50.7, 85.5)

74.7 (58.5, 96.3)

0.011

Triglycerides, mmol/L

1.3(1.0-1.7)

1.3(1.0-1.8)

0.428

Cholesterol, mmol/L

4.2(3.7–4.9)

4.4(3.7-5.0)

0.212

NT-proBNP, pg/mL

5210 (2217.5, 10,775)

3900 (1210, 7624)

0.004

WBC, ×10⁹/L

7.7 (6.4, 9.9)

8.1 (6.5, 10.9)

0.257

Lymphocytes,×10⁹/L

1.6(1.2,2.4)

1.7(1.3,2.5)

0.735

MPV

10.0(9.2,10.8)

9.9(9.3,10.9)

0.917

Hemoglobin, g/L

139 (125.0, 152.8)

146 (132.0, 157.0)

0.983

D-dimer, mg/L

1.9 (0.7, 3.0)

1.9 (0.9, 3.0)

0.429

Fibrinogen, mg/dL

3.9 (3.1, 4.1)

3.4 (2.9, 4.0)

0.125

LV ejection fraction, %

38.3 (29.5, 46.9)

38.0 (28.0, 48.0)

0.871

LVEDD, mm

51.7 (47.2, 58.6)

55.6 (48.5, 61.5)

0.078

LV aneurysm, n (%)

33 (22.9)

34 (19.9)

0.512

Area of mitral regurgitation, cm²

3.5 (1.7, 5.6)

3.5 (2.0, 5.9)

0.977

Thrombus size, mm²

265 (140.3, 421.3)

313.0 (159.0, 485.0)

0.144

Medication

Beta blockers, n (%)

116 (80.6%)

139 (81.3%)

0.869

ACEI, n (%)

96(66.7%)

105 (61.4%)

0.333

MRA, n (%)

75(52.1%)

81 (47.4%)

0.404

Duration of follow-up

23(10,35)

17(10,32)

-